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Abstract
Background—Methadone and buprenorphine are recommended to treat opioid use disorders
during pregnancy. However, the literature on the relationship between longer-term effects of
prenatal exposure to these medications and childhood development is both spare and inconsistent.

Author Manuscript

Methods—Participants were 96 children and their mothers who participated in MOTHER, a
randomized controlled trial of opioid-agonist pharmacotherapy during pregnancy. The present
study examined child growth parameters, cognition, language abilities, sensory processing, and
temperament from 0–36 months of the child’s life. Maternal perceptions of parenting stress, home
environment, and addiction severity were also examined.

Author Manuscript

Results—Tests of mean differences between children prenatally exposed to methadone vs.
buprenorphine over the three-year period yielded 2/37 significant findings for children. Similarly,
tests of mean differences between children treated for NAS relative to those not treated for NAS
yielded 1/37 significant finding. Changes over time occurred for 27/37 child outcomes including
expected child increases in weight, head and height, and overall gains in cognitive development,
language abilities, sensory processing, and temperament. For mothers, significant changes over
time in parenting stress (9/17 scales) suggested increasing difficulties with their children, notably
seen in increasing parenting stress, but also an increasingly enriched home environment (4/7
scales).
Conclusions—Findings strongly suggest no deleterious effects of buprenorphine relative to
methadone or of treatment for NAS severity relative to not-treated for NAS on growth, cognitive
development, language abilities, sensory processing, and temperament. Moreover, findings suggest
that prenatal opioid agonist exposure is not deleterious to normal physical and mental
development.
Keywords
opioid agonist medication; prenatal exposure; neonatal abstinence syndrome (NAS); early
childhood development

Author Manuscript

1. Introduction
Methadone and buprenorphine, if taken in adequate doses, can stabilize pregnant women
with opioid use disorder and prevent relapse (Hulse and O'Neil, 2002; Jones et al., 2010;
Jones et al., 2006; Kaltenbach et al., 1998). However, concern is often raised regarding
effects of such prenatal exposure to these medications on the developmental outcome of the
children. Studies to date have produced inconsistent findings. A review by Maguire and
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colleagues (Maguire et al., 2016) suggests that prenatal exposure to opioids may be
associated with deficits in cognition, psychomotor, and behavioral processes in infants and
young children. However, a review by Behnke and Smith (2013) found long-term effects on
behavior but no consensus on cognition and suggest studies with positive findings were
usually confounded by environmental factors. Most publications included in the reviews
have concerning methodological limitations (e.g., conflating different opioid exposures, not
controlling for tobacco and alcohol exposure) (Jones et al., 2015) and reported on crosssectional case-control studies in small, heterogeneous samples, with few prospective
longitudinal studies (Konijnenberg and Melinder, 2011).

Author Manuscript
Author Manuscript

Systematic reviews and meta-analyses (Brogly et al., 2014; Zedler et al., 2016) have
generally supported the contention that buprenorphine is superior to methadone in terms of
neonatal outcomes. Zedler and colleagues (Zedler et al., 2016) concluded that prenatal
exposure to buprenorphine relative to methadone has a lower risk of preterm birth, greater
birth weight, and larger head circumference. Brogly and colleagues (Brogly et al., 2014) also
report greater birth weight and larger head circumference as well as a higher mean
gestational age and a lower risk for treatment for neonatal abstinence syndrome (NAS) and
shorter length of hospital stay for buprenorphine than methadone-exposed neonates.
Neonates treated for NAS had a shorter duration of NAS treatment and a lower total dosage
of morphine dose in buprenorphine- than methadone-exposed neonates. Yet there are only
two studies to date that compare the outcome of children prenatally exposed to
buprenorphine to children prenatally exposed to methadone, both of which were
retrospective pediatric clinical chart reviews at birth and 4 months of age (Bier et al., 2015)
and through 2 years of age (Humbarger et al., 2016). To date, there are no studies that
prospectively examine developmental outcomes of children prenatally exposed to
buprenorphine compared to children prenatally exposed to methadone, although a
longitudinal study assessed visual evoked potential scores at 4 months of age (Whitham et
al., 2010) and at 3 years of age (Whitham et al., 2015) and found little difference between
buprenorphine and methadone exposure.

Author Manuscript

The question of the long-term effect of NAS has recently received new emphasis given the
rising opioid epidemic and the significant increase in prenatal opioid exposure (Patrick et al.,
2015). NAS has been used as an index of risk in recent legislation (Child Abuse Prevention
Act (CAPTA) of 2010; the Comprehensive Addiction and Recovery Act (CARA) of 2016)
resulting in potential consequences for mothers receiving opioid medication for treatment of
OUD while pregnant. However, the only study that has examined if developmental outcome
differs for infants who required treatment for NAS compared to infants who exhibited mid
NAS and required no treatment found no difference in development at 6 months of age
(Kaltenbach and Finnegan, 1986). There are no data regarding the effect of severity of NAS
on development during late infancy and early childhood.
The primary interest of the present study was threefold. First, to determine whether changes
in child growth parameters, cognition, language abilities, sensory processing, and
temperament over the 36-month period were differentially related to prenatal buprenorphine
versus methadone exposure. Significant results would indicate that the children develop
differently over the first three years of life as a result of exposure to one of the two opioid
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agonists. Second, to determine whether changes in child developmental outcomes over this
36-month period were differentially related to treatment for NAS. Significant results would
suggest that children who were treated for NAS as neonates develop differently over the first
three years of life as a result of NAS severity and/or exposure to morphine treatment. Third,
to determine the extent to which young children prenatally exposed to opioid agonist
medication follow a normal course of development and the extent to which maternal
perceptions of parenting stress, home environment, and addiction severity might have
changed over the three-year period.

Author Manuscript

This study examined secondary outcomes of child growth parameters, cognitive
development, language abilities, sensory processing, and temperament, and maternal
perceptions of parenting stress, home environment, and addiction severity during the child’s
first 36 months of life in a sample of 96 children and their mothers who participated in a
randomized controlled trial of opioid-agonist pharmacotherapy during pregnancy. This study
has multiple strengths relative to previous research: (1) the maternal sample is clearly
defined by study eligibility criteria; (2) use of substances other than either methadone or
buprenorphine during pregnancy was minimal; (3) both child and maternal functioning are
examined; (4) the potentially adverse impact on development of neonatal abstinence
syndrome (NAS) that requires treatment following prenatal exposure to either methadone
and buprenorphine is examined; and (5) it is longitudinal and prospective.

2. Methods
2.1 Maternal Opioid Treatment: Human Experimental Research (MOTHER) Study

Author Manuscript

Methodological aspects of the MOTHER trial relevant to this article, including the inclusion/
exclusion criteria and the CONSORT diagram, as well as maternal baseline characteristics
and secondary neonatal and maternal outcomes (i.e., amount of prenatal care, positive drug
screen at delivery, etc.) have already been published (Jones et al., 2012; Jones et al., 2010).
MOTHER (Jones et al., 2010) was a double-blind, double-dummy, flexible-dosing, twogroup randomized controlled trial. Either methadone or buprenorphine was provided to 175
opioid-dependent pregnant women with a singleton fetus (6–30 weeks), of whom 58 women
in the buprenorphine and 73 in the methadone condition delivered an infant while enrolled in
the study. Buprenorphine (2–32 mg) and methadone (20–140 mg) dosing followed a flexible
dose protocol (Jones et al., 2010).

Author Manuscript

NAS assessment was performed for all infants for a minimum period of 10 days postdelivery. The MOTHER NAS Scale (MNS) (Jones et al., 2010) measured NAS.
Supplementary Material1 (Jones et al., 2010) and Table 2 in Weaver and colleagues (Weaver
et al., 2014) provide MNS development and scoring principles. Jones and colleagues (Jones
et al., 2010) provide rater training and inter-rater agreement information. The NAS treatment
protocol was based on MNS scores. Neonates requiring pharmacotherapy were treated with
oral morphine sulfate.

1Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by entering doi:…
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The present study was approved by the Institutional Review Boards of the participating sites:
Brown University, Johns Hopkins University, The Medical University of Vienna, the
University of Vermont, Thomas Jefferson University and the City of Philadelphia, Vanderbilt
University, and Wayne State University. Study participants were recruited at study sites
following completion of MOTHER participation. Examiners trained in developmental
evaluations assessed infants and research staff assessed mothers. All assessments were
conducted at the hospital sites and all examiners were blind to the maternal-infant
Medication Condition.
2.3 Measures and assessment schedule

Author Manuscript

Measures were a multidimensional set of well-validated instruments that are widely used
both for clinical diagnoses and research assessment, with child measures of developmental
outcomes focusing on growth parameters, cognitive development, sensory processing,
temperament, and language abilities. Maternal measures focused on perceptions of parenting
stress, home environment, and addiction severity. Assessments were conducted when infants
were 3, 6, 12, 24, and 36 months of age. Table 1 includes descriptions of measures and their
assessment schedule. Because first enrollment in MOTHER occurred in May 2005 and the
follow-up National Institute on Drug Abuse supplement award for this study was not
received until Spring 2008, some infants were too old to be administered the assessment
battery at the early ages, and the assessment battery was not administered to some infants at
the later ages due to study close-out before they reached three years of age.
2.4 Statistical analyses

Author Manuscript
Author Manuscript

For all outcomes except child growth parameters, the statistical model had two fixed
between-subject factors, Treatment (Buprenorphine v. Methadone), NAS Treatment (Treated
v. not-Treated), and one fixed within-group factor for assessment Time point. [The Time
effect could involve up to 5 levels (3 months v. 6 months v. 12 months v. 24 months v. 36
months). Not all outcomes were measured on all occasions; for these latter outcomes, Time
included only a subset of these 5 levels, as appropriate to the assessment schedule for that
outcome (see Table 1).] The statistical model for the three growth parameters also includes a
fixed effect for child Sex. A linear mixed model (Littell et al., 2006; Verbeke and
Molenberghs, 2000) examined the main effects and their respective interactions, assuming
the outcome measures were normally distributed. To maximize detection of differences
associated with each test of significance, the Type I error rate was set to .05 for all main and
interaction tests of significance. Post hoc testing for interaction effects involved testing
simple interaction or simple main effects, followed by testing pairwise mean differences, as
appropriate to the outcome (Kirk, 2013). Post hoc testing for the Time main effect involved
testing for linear trend and deviations from linearity to determine if change over time
followed a systematic linear or non-linear progression or retrogression, with the spacing for
the polynomial determined by the month of assessment, given the assessments were not
conducted with equal intervening lengths of time. Sidak’s adjustment (Kirk, 2013; Šidák,
1967) was applied to all post hoc tests. All analyses were performed with SAS version 9.3.
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There were three effects of interest for all outcomes: Medication Condition X Time
interaction, NAS Treatment X Time interaction, and the Time main effect. The Medication
Condition X Time interaction tested whether the change over the three-year period differed
between the Buprenorphine and Methadone conditions. The NAS Treatment X Time
interaction tested whether the change over the three-year period differed between the
Treated- and not- Treated-for-NAS groups (for the child in the case of child outcomes and
for the mothers in the case of maternal outcomes, respectively). The Time main effect tested
for change over the three-year period, and assessed the general growth and development of
the children. The associated tests for linearity assessed whether change in the outcome
measure over time was uniform (e.g., followed a uniform or straight-line pattern).

Author Manuscript

Therefore, Other Effects, discussed in the Results, refer to those effects other than the
Medication Condition X Time interaction effect, the NAS Treatment Group X Time
interaction effect, and the Time main effect.
The principal focus in this study was on the child measures, as there was no research basis to
expect maternal effects. Maternal effects were examined to help contextualize child
differences, particularly to the extent the latter changed over time.
2.5 Minimum detectable effect size
To provide some context for examining results in addition to P values, we calculated the
minimum detectable effect size, f2 (Cohen, 1988), for each effect in the statistical model.
Table 2 displays the resulting effect size estimates f2.

3. Results
Author Manuscript

3.1 Participants

Author Manuscript

This subsample largely reflects the MOTHER sample as a whole. The maternal participants
were relatively young [M=26.1 (SD=5.4)], with 75/96 (78%) less than 30 years of age],
majority White [90/96 (94%)], with 39/96 (41%) having less than a high school education
[years of education M=11.5 (SD=2.1)], largely unemployed [76/96 (79%)] and never
married [71.96 (74%)]. They were maintained on their agonist medication as part of study
participation for almost 20 weeks [M=143.7 (SD=41.4) days in the buprenorphine condition,
M=136.0 (SD=57.7) days in the methadone condition, p>.4]. Overall, neonates were healthy
[5-minute Apgar M=9.1 (SD= .9), with 3/96 (3%) having a 5-minute Apgar ≤ 7], only 8/96
(8%) born prior to early term [estimated gestational age at delivery M=38.8 (SD=2.0)]. In
addition, 54/96 (56%) neonates were treated for NAS; for these 54 neonates, NAS treatment
lasted for an average of almost two weeks [M=16.9 (SD=15.4)]. Of the original 131
MOTHER participants, 52/73 methadone and 44/58 buprenorphine condition participants
provided longer-term follow-up data, p>.5. Relative to present study non-participants, study
participants were more likely to be White (94% v. 71%, p< .001), less likely to be
unemployed (79% v. 99%, p= .013), with neonates with a higher mean 5-minute Apgar
[M=9.1 (SD= .9) v. M=8.5 (SD=1.3), p< .002], later mean gestational age at delivery
[M=38.8 (SD=2.0) v. M=37.4 (SD=2.9), p< .002], and a shorter mean duration of NAS
treatment [M=13.2 (SD=10.9) v. M=31.4 (SD=21.3), P< .001].
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The data reported in this paper are unique because they present findings on the largest and
most comprehensive assessment of neonates prenatally exposed to agonist medications, with
minimal to no additional drug exposure. Thus, a set of Supplementary Tables2 for child and
maternal outcomes are included. These tables contain the test statistics and P values and the
associated estimated marginal means and 95% confidence intervals for all effects except the
Medication Condition X NAS Treatment and Medication Condition X NAS Treatment
Group X Time interactions.
3.2.1 Child results
3.2.1.1 Medication Condition X Time Effects: There were two significant Medication
Condition X Time interaction effects.

Author Manuscript

3.2.1.2 Receptive-Expressive Emergent Language Test – Third Edition: The Medication
Condition X Time interaction effect was significant for the REEL-3 Receptive Percentile
Rank. Means showed a distinct pattern in which the percentile rank mean for the
Buprenorphine Condition was significantly lower than the percentile rank mean for the
Methadone Condition at 12 months [M=28.8 (SE=5.9) v. M=45.9 (SE=5.0), respectively, p<.
03], with percentile rank means of the two conditions rising and closing with each other at
24 [M=70.9 (SE=4.4) v. M=60.2 (SE=4.5), respectively, p>.09] and 36 months [M=67.2
(SE=4.9) v. M=64.5 (SE=4.1), respectively, p>.66] (see Supplementary Table S33).

Author Manuscript

3.2.1.3 Infant Behavior Questionnaire Revised: The Medication Condition X Time
interaction effect was significant for the IBQ-R Approach scale, largely due to the fact that
the Buprenorphine Condition mean was significantly lower than the Methadone Condition
mean at 3 months [M=4.1 (SE=0.2) v. M=5.0 (SE=0.3), respectively, p=< .03, while the
means of the two conditions at 6 [M=5.5 (SE=0.2) v. M=5.3 (SE=0.2, respectively, p>.5] and
12 months [M=6.0 (SE=0.2 v. M=6.1 (SE=0.2), respectively, p=>.8] were not significantly
different from one another (see Supplementary Table S33).
3.2.2 NAS Treatment Group X time effects—There was one significant NAS
Treatment Group X Time interaction effect.

Author Manuscript

3.2.2.1 Infant Behavior Questionnaire Revised: The NAS Treatment Group X Time
interaction effect was significant for the IBQ-R Distress to Limitations scale. Examination of
the means showed that the Treated-for-NAS group means were higher than the not-Treatedfor-NAS group at 6 months [M=3.9 (SE=0.2) v. M=3.3 (SE=0.3), respectively, p< .05] but
not at 3 [M=3.7 (SE=0.2) v. M=3.3 (SE=0.3), respectively, p=>.2] and 12 months [M=4.1
(SE=0.2) v. M=4.4 (SE=0.2), respectively, p>.2] (see Supplementary Table S33).

2Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by entering doi:…
3Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by entering doi …
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3.2.3 Time main effects—Test statistics, P values, and the estimated marginal means and
their 95% confidence intervals for the Time main effect for growth parameters are given in
Table 3 for growth parameters and in Table 4 for developmental outcomes.
3.2.3.1 Growth parameters: Mean z-scores for weight, height, and head circumference
increased from 3 to 36 months (see Table 3). Beginning below the 50th percentile at 3
months and ending exceeding the 50th percentile at 36 months – and, in the case of weight
and head circumference, significantly higher than the 50th percentile.

Author Manuscript

3.2.3.2 BSID-III: The Time effect was significant for nine of 10 BSID-III scales, the
exception being the General Adaptive Percentile Rank Score (see Table 4). Changes over the
period from 6 to 36 months for these nine scales could not be considered consistent (see
Supplementary Table S64 for tests of linearity) – the only exception being the Cognitive
Percentile Rank Score, which showed a general decline over the time period. However, six
of the nine significant scales - excepting Motor Composite and General Adaptive Composite
Scores and Social-Emotional Percentile Ranks – showed non-uniform change (see
Supplementary Table S64 for tests of deviations from linearity), with means reflecting a
weak decline and then a general upturn in scores at 36 months.
3.2.3.3 REEL-3: Three of the five REEL-3 measures showed significant changes over Timethe two Receptive Scores and the combined Language Ability Score (see Table 4). All three
measures showed non-uniform changes over the period from 12 to 36 months (see
Supplementary Table S64). Examination of the means suggested an increase in mean scores
for the three significant measures from 12 to 24 months, leveling off from 24 to 36 months.

Author Manuscript

3.2.3.4 ITSP: Only two of four significant ITSP scales – Sensation Avoiding and Low
Threshold – showed significant change over Time (see Table 4) that could be seen as
showing a consistent pattern or as deviations from a consistent pattern of change (see
Supplementary Table S65). For both scales, change was non-uniform. Examination of the
means indicated that for both scales, there was a pronounced change from 6 to 12 months,
flattening out at 24 months, and then an increase at 36 months.
3.2.3.5 IBQ-R: Of the 14 IBQ-R scores, eight tests of Time were significant (see Table 4).
Seven of these eight scales showed consistent increases from 3 to 12 months (see
Supplementary Table S65). In contrast, Cuddliness showed a consistent decline over this
period. The rate of change for Activity Level rose from 3 to 6 months, and remained
unchanged from 6 to 12 months.

Author Manuscript

3.2.4 Other effects—There were three significant Other Effects: One Sex X NAS
Treatment Group interaction effect, one NAS Treatment Group main effect, and two
significant Medication Condition X NAS Treatment effects.

4Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by entering doi:…
5Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by entering doi:…
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3.2.4.1 Growth parameters: There was a significant Sex X NAS Treatment Group
interaction effect for head circumference, although the means were found not to significantly
differ from each other, with all ps>.05 The pattern of means would suggest that the
interaction arose due to the fact that girls had a slightly larger head circumference in the notTreated-for-NAS group [M=0.47 (95% CI: −0.08, 1.03), Percentile= .61] than in the
Treated-for-NAS group [M=−0.17 (95% CI: −0.54, 0.20), Percentile=.45], while boys had
slightly larger head circumference in the Treated-for-NAS group [M=0.24 (95% CI: −0.18,
0.65), Percentile=.56] than in the not-Treated-for-NAS group [M=−0.20 (95% CI: −0.62,
0.23), Percentile=.47].
3.2.4.2 Infant Toddler Sensory Profile: The NAS Treatment Group main effect was
significant for the ITSP Sensation Seeking scale, with the not-Treated-for-NAS group mean
significantly higher than the mean for the Treated-for-NAS group.

Author Manuscript

3.2.4.3 Infant Behavior Questionnaire Revised: The Medication Condition X NAS
Treatment interaction effect was significant for IBQ-R Distress to Limitations and Sadness
scales. Examination of the means for the IBR-Q Distress to Limitations scale indicated that
the only significant mean difference was that the mean for the Treated-for-NAS group was
larger than the mean of the not-Treated-for-NAS group. For the Sadness scale, the four
means were not found to be significantly different from one another. The pattern of means
would suggest that the interaction arose due to the fact that the not-Treated-for-NAS group
had a smaller mean than did the Treated-for-NAS group in the Methadone condition, while
the not-Treated-for-NAS group had a larger mean than did the Treated-for-NAS group in the
Buprenorphine condition.

Author Manuscript

3.2.5 Supplementary Results—Supplementary Table S16 contains the test statistics and
P values for the child growth parameters while Supplementary Table S26 contains the test
statistics and P values for the cognition, language abilities, sensory processing, and
temperament. Supplementary Table S36 contains the associated estimated marginal means
and 95% confidence intervals for these latter outcomes for all effects except the Medication
Condition X NAS Treatment and Medication Condition X NAS Treatment Group X Time
interactions.
3.2.6 Maternal results
3.2.6.1 Medication Condition X time effects: There was one significant Medication
Condition X Time interaction effect.

Author Manuscript

3.2.6.2 Addiction Severity Index: Examination of the means for the ASI Legal composite
score indicated a general pattern in which the means for both conditions fell off over the
period from 3 to 36 months (Ms=0.03, 0.08, 0.01, 0.00, and 0.01 for the Buprenorphine
condition respectively and Ms=0.10, 0.13, 0.10, 0.12, and 0.05 respectively for Methadone
condition), but the Buprenorphine condition had significantly lower mean scores at 12 and
24 months than did the Methadone condition [M= .01 (SE=.03) v. M=.10 (SE=.03) at 12

6Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by entering doi:…
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months respectively, p<.03; M=.00 (SE.03) v. M= .12 (SE=.03) at 24 months respectively,
p<.002] (see Supplementary Table S57).
3.2.6.3 NAS Treatment Group X time effects: There was one significant NAS Treatment
Group X Time interaction effect.
3.2.6.4 Addiction Severity Index: The ASI Legal composite score showed significant
differences between the means of Time within the not-Treated-for-NAS group [Ms=0.08,
0.15, 0.07, 0.05, and 0.01, respectively; F(4,69)=4.2, p<.005}, but not for the means of Time
within the Treated-for-NAS group [Ms= 0.05, 0.05, 0.05, 0.06, and 0.05, respectively;
F(4,69)=0.2, p>.9] (see Supplementary Table S57).

Author Manuscript

3.2.7 Time main effects—Table 5 presents the test statistics, P values, and the estimated
marginal means and their 95% confidence intervals for the Time main effect for all maternal
outcomes.
3.2.7.1 PSI: PSI scores showed significant changes for nine of seventeen scales over Time,
largely indicative of increased stress from child behaviors as the child enters the toddler
stage and corresponding stress associated with parenting competence (see Table 5).
3.2.7.2 HOME: HOME scores showed significant changes for four of seven scales over
Time (see Table 5), with scores rising from 6 to 24 to 36 months for those variables that
were significant, as seen in the HOME total score (see Table 5).
3.2.7.3 ASI: There was no significant change over Time for the ASI composite scores (see
Table 5).

Author Manuscript
Author Manuscript

3.2.8 Other Effects—There were 14 significant Other Effects. 3.2.8.1 Parenting Stress
Index. There was a significant main effect for NAS Treatment Group for the PSI Reinforces
Parent scale, with the mean for the Treated-for-NAS group significantly higher than the
mean for the not-Treated-for-NAS group. There were significant Medication Condition X
NAS Treatment Group interaction effects for the PSI Adaptability and Health scales. The
PSI Adaptability mean was significantly higher for mothers in the Methadone condition
whose neonates were Treated-for-NAS than the mean for the mothers in the Methadone
condition whose neonates were not-treated-for-NAS, while the remaining three tests of the
mean differences were nonsignificant. Regarding the PSI Health scale, post hoc testing
indicated all simple mean differences were nonsignificant. There was a significant
Medication Condition X NAS Treatment Group X Time interaction effect for the PSI Health
scale. The simple interaction of Medication Condition X NAS Treatment at each level of
Time was only significant at 6 months; however, none of the mean differences at 6 months
were significant.

7Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by entering doi:…
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3.2.8.2 Home Observation for Measurement of the Environment: There was a significant
Medication Condition main effect for HOME Organization, with the mean of the
Buprenorphine condition significantly higher than mean for the Methadone condition.

Author Manuscript

3.2.8.3 Addiction Severity Index: There were significant Medication Condition main
effects for the ASI Alcohol and Legal composite scores. For Alcohol, the Buprenorphine
condition mean was significantly larger than the Methadone condition mean, while for
Legal, the Buprenorphine condition mean was significantly smaller than the Methadone
condition mean. There were significant NAS Treatment group main effects for the ASI
Employment and Family/Social composite scores. For both ASI composite scores, the
Treated-for-NAS group means were significantly larger than the not-Treated-for-NAS group
means. The Medication Condition X NAS Treatment group interaction effect was significant
for the ASI Medical composite score. The mean for the mothers whose neonates were
Treated-for-NAS was significantly higher than the mean for the mothers whose neonates
were not-treated-for-NAS, while the remaining tests of differences between the means were
non-significant. The Medication Condition X NAS Treatment X Time interaction effect was
significant for both the ASI Medical and Alcohol composite scores. For the Medical
composite, the interaction was due to the fact that the means for both the Treated-for-NAS
and not-Treated-for-NAS groups in the Buprenorphine condition rose over the three-year
period, while this was not the case in the Methadone condition. In contrast, the interaction
for the Alcohol composite was due to the fact that the means at 6 months was substantially
lower in both the Treated-for-NAS and not-Treated-for-NAS groups in the Buprenorphine
condition than the corresponding means in the Methadone condition

Author Manuscript

3.2.9 Supplementary results—Supplementary Table S48 contains the test statistics and
P values for maternal parenting stress, home environment, and addiction severity measures.
The estimated marginal means and 95% confidence intervals for all effects except the
Medication Condition X NAS Treatment and Medication Condition X NAS Treatment
Group X Time interactions are reported in Supplementary Table S5.

4. Discussion
Overall, this study found that from 3 months through 36 months of age, children prenatally
exposed to buprenorphine or methadone were well within the range of normal development
in physical growth measures, cognitive development and language development. Also,
mothers maintained on buprenorphine or methadone did not differ on any of the measures,
other than the ASI legal section.

Author Manuscript

4.1 Child findings
In this study, up to 36 months, children follow a path of normal development. Thus, findings
for growth parameters suggest that prenatal opioid agonist exposure does not affect normal
physical development. Conclusions are similar in terms of cognitive development, language
abilities, sensory processing, and temperament. Changes over time in some, though not all

8Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by entering doi:…
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Bayley mean composite scale and percentile rank scores as well as the ITSP scale scores,
with a general upturn in scores at 36 months, argue against any conclusion of some overall
pattern of loss of abilities in these areas.
Moreover, significant changes over time in the mean scores did not indicate any substantive
developmental decline. Mean scores continued to be within the average range. The changes
in language ability found in the Bayley language composite scale indicate that language
development was within normal limits.

Author Manuscript

There are two significant Medication Condition X Time and one significant NAS Treatment
Group X Time interaction, out of 37 such tests conducted for each effect. These results offer
strong support for two conclusions. First, there is no apparent pattern of results that would
argue for differential impact of prenatal exposure to methadone or buprenorphine on early
childhood growth and development. Second, NAS severity does not have an adverse impact
on early childhood growth and development. This finding is consistent with a previous study
in neonates prenatally exposed to methadone (Kaltenbach and Finnegan, 1987) and provides
important contemporary information for clinicians and policymakers.
4.2 Maternal findings

Author Manuscript

Maternal findings strongly indicated that, on average, neither methadone and buprenorphine
mothers nor the mothers whose neonate was or was not treated for NAS differed from each
other in terms of any characteristic over the three-year period, with the possible exception of
ASI-defined legal problems. Scores on the PSI would suggest that the mothers, as a group,
reported increasing difficulties with their children over the three-year period, notably seen in
increasing Child Domain mean scores and increases in the parental competence mean score.
It is unclear whether the children actually exhibit more challenging behaviors; whether
mothers who experience high levels of parenting stress rate typical child behaviors as more
severe; or whether the relationship is bi-directional. In contrast to the PSI findings, HOME
scores show a consistently more enriched home environment over the period from 6 to 36
months. Taken together, these results counteract the assumption that mothers with a history
of opioid use disorder are unable to create a positive home environment (Kaltenbach, 2013)
and suggest that developmental risk for their children may be related more to problems in
the parent-child relationship.
4.3 Limitations

Author Manuscript

The study has several limitations. First, only 96 of the 131 women who participated in the
MOTHER trial were recruited. While the subsample appears to be largely representative of
the MOTHER sample, it is possible that unknown factor(s) may have operated to impact
subsampling that may have biased the findings. Second, constraints placed on sampling due
to cost and time limitations led to not all of the 96 mothers and their children being
measured at each time point. Further, this sample size limited the statistical model
complexity (e.g., no control for recruitment site, for child variables, or maternal covariates).
Third, the MOTHER study emphasized internal, not external, validity, so the ability to
generalize the current findings may be limited. However, the MOTHER sample was unique
in that, with the exception of tobacco, there was minimal to no concomitant prenatal
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substance exposure, including alcohol. Fourth, the subsample of MOTHER mothers and
infants examined in this paper may differ in important ways from the MOTHER women and
infants who were non-participants. Inclusion of non-participants could have impacted
findings in unknown ways. Fifth, there was no comparison group of mother and children
whose mothers were of similar socioeconomic status who did not use psychoactive
substances. Lastly, the per-comparison α was set at .05, and as a result, the cumulative error
rate in the study may be sizeable, with some unknown number of findings Type I errors.
However, α was set at .05 in order to maintain our ability to detect relatively weaker
medication and NAS treatment effect differences- effect sizes determined to be in the smallto-medium range (see Table 2). Setting α to some value lower than .05 would have
prevented detection of weaker relationships that might prove important to examine in future
research.

Author Manuscript

5. Conclusions
The present study is the first longitudinal study to examine early childhood developmental
outcomes of infants born to pregnant women who were enrolled in a randomized, controlled
trial examining maternal treatment with methadone or buprenorphine with rigorous
assessment and treatment protocols for NAS. Findings suggest that children prenatally
exposed to opioid agonist medications follow a pattern of normal development during the
first three years of life. These results are consistent with studies that find no differences in
development between infants prenatally exposed to opioids and non-exposed infants. They
also provide important comparison data to studies that have reported differences as such
studies have all been confounded by multiple illicit and licit drugs.

Author Manuscript

Findings strongly suggest no deleterious effects for buprenorphine relative to methadone.
Findings also strongly indicate no deleterious effects for NAS requiring treatment relative to
not-treated-for-NAS in children 0–3 years old prenatally exposed to opioid agonist
medication as part of a randomized controlled trial. Over the first three years, mothers in
general struggled with parenting skills at the same time they reported they were able to
provide an increasingly enriched home environment to address child needs. Findings suggest
future research could profitably focus on intervention trials that examine the impact of
parenting practices and parent training on the development of children who are prenatally
exposed to opioid agonist medications.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
•

Children exposed to opioids in utero exhibit normal development in early
childhood

•

There was no difference in development between methadone and
buprenorphine exposure

•

Neonatal Abstinence Syndrome (NAS) severity did not have an effect on early
childhood growth and development
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Assessment Instruments and Assessment Schedule
Assessment
Time Point
(month)

Child Measures
Growth Measurements: Weight (gm), Height (in), Head Circumference (cm) (See Table 2 for an explanation of the
transformation of these outcomes for purposes of analysis.)
Bayley Scale of Infant Toddler Development III (BSI-III):25 The BSI-III provides an extremely thorough, standardized
assessment of infant development. In the present paper we report Cognitive, Language, Motor, Social-Emotional, and
Adaptive Behavior scores. The composite scores are norm-referenced and standardized with a mean of 100 and a standard
deviation of 15.

3, 6, 12, 24, 36
6, 12, 24, 36

Author Manuscript

Receptive-Expressive Emergent Language (REEL)-3:26 The REEL-3 is a 66-item, norm-referenced test administered to
caregivers, developed to identify young children who have developmental problems in use or understanding of language. It is
composed of two subtests, for emerging receptive and expressive language skills. The present paper reports on the Receptive
and Expressive Ability scores and percentile ranks, and the Language Ability scores. The three Ability scores are scored
according to population norms, in a manner similar to intelligence tests, with means of 100 and standard deviations of 15.

12, 24, 36

Infant Toddler Sensory Profile (ITSP):27 A standardized instrument for assessing a child’s sensory processing abilities and to
profile the effect of sensory processing on functional performance in daily life. There are 36 items for children 0–6 months,
and 48 items for children 7–36 months. There are four quadrants: Low Registration (13 items for 0–6 month form; 11 items
for 7–36 month form), Sensation Seeking (6; 14), Sensory Sensitivity (12; 11), and Sensation Avoiding (5; 12), and a Low
Threshold score representing a sum of the Sensory Sensitivity and Sensation Avoiding quadrant scores. Quadrant scores are
computed by summing the responses to each item on a 5-point scale, ranging from 1 (“Almost always”) to 5 (“Almost
never”), so that lower scores indicate relatively more functional problems in a given area of sensory processing.

3, 6, 12, 24, 36

Infant Behavior Questionnaire Revised (IBQ-R):28,29 A 91-item inventory of infant behavior in 14 domains: Activity Level;
Distress to Limitations; Fear; Duration of Orienting; Smiling and Laughter; High Intensity Pleasure; Low Intensity Pleasure;
Soothability; Falling Reactivity/Rate of Recovery from Distress; Cuddliness; Perceptual Sensitivity; Sadness; Approach; and
Vocal Reactivity. Respondents score the frequency of infant behavior on a scale of 1 (“Never”) – 7 (“Always”). Scores on
each domain are the mean of the item ratings in that domain, so in some cases, higher scores indicate more of a negative
behavior (eg, Fear) while in other cases, higher scores indicate more of a positive behavior (eg, Cuddliness).

3, 6, 12

Maternal Measures

Author Manuscript

Parenting Stress Index (PSI):30 A 120-item inventory of parental stress in three domains: Child, with 6 subscales
(Distractibility/Hyperactivity, Adaptability, Reinforces Parent, Demandingness, Mood, and Acceptability) that measures
sources of stress from child behavior, as reported by the parent; Parent, with 7 subscales (Competence, Isolation, Attachment,
Health, Role Restriction, Depression, and Spouse/Parenting Partner Relationship) that measure sources of stress related to
parent functioning; and a Life Stress scale that measures the amount of parent stress caused by situational factors other than
from the child or parent. The Child and Parent domains combine to yield the Total Stress scale. The 101 Child and Parent
items are each scored on a 5-point scale (1 “Strongly Agree” – 5 “Strongly Disagree”), with the 19 Life Stress item responses
indicating whether the events have occurred (0 “No” 1 “Yes:) in the past 12 months. Higher scores for each subscale and the
two domain scores and the total score reflect more stress in that area.

3, 6, 12, 24, 36

Infant Toddler Home Observation for Measurement of the Environment (ITHOME):31 A 45-item inventory measuring 6
domains of the home environment important to child development: Responsivity (11 items) Acceptance (8), Organization (6),
Learning Materials (9), Involvement (6), and Variety (5). Each domain has a separate score ranging from 0 to the number of
items in the respective scale; the domain scores are then added to yield a Total Score (range: 0–45), with higher scores
indicating a relatively more enriched home environment.

6, 24, 36

Addiction Severity Index (ASI):32 A clinical assessment of addiction severity that measures functioning in 7 areas of the
respondent’s life: Medical, Employment, Drug, Alcohol, Legal, Family/Social, and Psychiatric. Items from each section are
weighted and contribute to a composite score for each area, with scores ranging from 0–1, with higher scores indicating
greater problem severity.

Author Manuscript
Drug Alcohol Depend. Author manuscript; available in PMC 2019 April 01.

3, 6, 12, 24, 36

Kaltenbach et al.

Page 18

Table 2

Author Manuscript

Estimates of Effect Size f2 for Effects in the Inferential Statistical Model for 3, 4, and 5 Occasions of
Measurement for N= 96 observations, α=0.05, and power (1−β)=0.80
Number of Measurement Occasions

Author Manuscript

3

4

5

Medication Condition (M)

.104

.119

.131

Treated-for-NAS Group (N)

.104

.119

.131

Time (T)

.065

.071

.070

M×N

.104

.119

.131

M×T

.065

.071

.070

N×T

.065

.071

.070

M×N×T

.065

.071

.070

Effect

Note. Effect Size f2 was estimated using the set correlation method. See text for details.
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20.3

48.0

Height

Head Circuference

<.001

<.001

<.001

P

−0.89

−1.09

−0.41

M

(−1.43, −.0.35)

(−1.85, −0.33)

(−0.92, 0.10)

95%
CI

0.26

0.25

0.39

Perce
ntile

−0.30

−0.40

−0.33

M

(−0.66, 0.58)

(−0.77, −0.01)

(−0.67, 0.01)

95% CI

6
months

0.42

0.40

0.43

Percen
tile

0.31

−0.37

−0.33

M

(−0.04, 0.65)

(−0.89, 0.16)

(−.70, 0.03)

95%
CI

12
month
s

0.59

0.42

0.43

Perce
ntile

0.58

−0.19

0.23

M

(0.29, 0.86)

(−0.59, 0.20)

(−0.04, 0.51)

95%
CI

24
mont
hs

0.64

42.00

0.55

Perce
ntile

0.74

0.43

0.64

M

(0.44, 1.04)

(0.04, 0.80)

(0.29, 0.98)

95%
CI

36
mon
ths

0.70

0.60

0.68

Perce
ntile

measures were assumed to be normally distributed in the population, so normal-theory-based estimation and tests of significance were utilized. Test statistics are Wald χ2 tests of significance for the test of the Time main effect for the respective growth parameter. Summary data
presented in this table are the mean z-scores (M) and their 95% confidence intervals (95% CI), together with their corresponding mean percentiles (Percentile). The mean z scores indicates the distance in standard deviation units the sample means were at the given time point
from the normative sample means found in the CDC growth charts. Thus, for example, the mean z-score weight for the sample at 3 months was −0.41, indicating that the sample was .41 standard deviations below the normative sample mean. The Percentile score indicates the
percentage of the normative sample estimated to be at or below that z-score. Thus, a percentile of 0.39 at 3 months for weight indicates that 39% of the normative sample fall at or below the z-score of −0.41. z-scores were used in all inferential analyses. Analysis of z-scores
allowed for the inclusion of data from both girls and boys in the same analysis, and allowed for testing whether the z-score at each time period was 0, that is, whether the deviation from the 50th percentile at each time period was significant. (All such tests were conducted using
the standard error for the respective mean z-score, with Sidak's post hoc adjustment.) Mean z-scores in bold indicate that the mean for the highlighted cell was significantly lower (in the case of height and head circumference at 3 months) or significantly higher (for weight at 36
months and head circumference at 24 and 36 months) than the 50th percentile reported for the normative date by the CDC (see http://www.cdc.gov/growthcharts/percentile_data_files.htm for US growth charts).

Notes. Raw data for each of the three growth parameters were transformed to z-scores and percentiles for the purposes of analysis (see http://www.cdc.gov/growthcharts/percentile_data_files.htm for more information and the formula needed for the transformations). All

32.1

Weight

χ2

3
mon
ths

Time

Growth Parameters: Wald χ2 Tests of Significance, P Values, and Estimated Marginal Means (95% Confidence Intervals) and Mean Percentile for the Time Main Effect (N=96)
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19.2
20.6
18.6
10.8
13.4
12.0
9.8
8.4
7.6

Cognitive Subtest Percentile Rank

Language Composite Score

Language Percentile Rank

Motor Test Composite Score

Motor Test Percentile Rank

Social-Emotional Scale Composite Score

Social-Emotional Scale Percentile Rank

General Adaptive Composite Score

General Adaptive Percentile Rank

0.06

0.04

0.02

0.01

0.004

0.01

<.001

<.001

<.001

0.01

P

M

95% CI

3 months
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46.8
1.7
5.1
12.3

Receptive Percentile Rank

Expressive Ability Score

Expressive Percentile Rank

Language Ability Score

8.9
19.1
17.8

Sensation Avoiding

Low Threshold

Sensation Seeking

Sensory Sensitivity

25.4
142.9

Low Registration

Infant Toddler Sensory Profile (ITSP):

29.6

Receptive Ability Score

<.001

<.001

0.06

<.001

<.001

0.002

0.08

0.44

<.001

<.001

72.3

22.1

49.7

9.2

49.5

(68.97, 75.73)

(20.26, 23.94)

(46.93, 52.56)

(6.54, 11.92)

(46.17, 52.74)

Receptive-Expressive Emergent Language Test-Third Edition (REEL-3):

12.7

χ2

Cognitive Subtest Composite Score

Bayley Scale of Infant Development (BSID-III):

Time:

69.7

21.3

49.7

7.8

49.6

58.3

104.6

70.2

114.2

50.6

99.3

54.8

102.4

57.9

103.1

M

(65.66, 73.74)

(19.76, 22.89)

(47.78, 51.66)

(6.73, 8.95)

(47.87, 51.42)

(49.18, 67.38)

(99.75, 109.37)

(60.40, 80.00)

(108.13, 120.24)

(43.02, 58.11)

(95.55, 103.10)

(47.16, 62.45)

(98.72, 106.01)

(51.02, 64.80)

(99.58, 106.58)

95% CI

6 months

88.2

47.1

41.6

23.6

46.6

96.6

47.5

99.2

37.4

94.1

51.2

100.8

53.6

102.0

37.3

94.3

41.8

96.5

47.6

98.6

M

(83.37, 93.01)

(44.48, 49.80)

(39.13, 44.00)

(20.98, 26.16)

(44.10, 49.16)

(91.56, 101.70)

(37.83, 57.21)

(94.54, 103.87)

(29.71, 45.06)

(89.53, 98.70)

(42.59, 59.81)

(96.20, 105.31)

(44.00, 63.14)

(96.06, 107.92)

(29.93, 44.76)

(90.63, 98.05)

(34.08, 49.53)

(92.83, 100.19)

(40.83, 54.29)

(95.21, 102.02)

95% CI

12 months

89.1

47.6

41.7

29.6

45.7

106.3

53.2

101.8

65.5

108.8

44.8

97.1

61.5

107.1

48.5

99.8

35.3

92.7

40.7

96.3

M

(85.31, 92.99)

(45.50, 49.65)

(39.72, 43.74)

(27.33, 31.82)

(43.72, 47.72)

(102.24, 110.44)

(45.48, 60.87)

(97.98, 105.56)

(59.27, 71.76)

(105.14, 112.56)

(37.20, 52.34)

(93.08, 101.10)

(53.62, 69.40)

(102.23, 111.92)

(42.18, 54.84)

(96.61, 102.95)

(28.87, 41.70)

(89.62, 95.73)

(34.86, 46.57)

(93.30, 99.33)

95% CI

24 months

92.8

49.8

43.3

35.3

47.4

104.8

60.4

102.6

65.9

105.2

51.2

100.6

53.5

102.4

52.8

101.6

46.1

98.4

44.4

98.5

M

(88.83, 96.72)

(47.57, 52.04)

(41.33, 45.21)

(32.88, 37.71)

(45.38, 49.34)

(100.77, 108.88)

(52.77, 67.95)

(98.85, 106.35)

(59.52, 72.21)

(101.47, 109.02)

(43.40, 59.02)

(96.46, 104.74)

(45.36, 61.68)

(97.38, 107.41)

(46.25, 59.34)

(98.29, 104.85)

(39.57, 52.61)

(95.25, 101.47)

(38.45, 50.45)

(95.41, 101.57)

95% CI

36 months

Child Mental Development, Language Abilities, Sensory Processing, and Temperament Measures: Wald χ2 Tests of Significance, P Values, and
Estimated Marginal Means (95% Confidence Intervals) for the Time Main Effect (N=96)

Author Manuscript
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32.0
13.2

Cuddliness

Perceptual Sensitivity

<.001

<.001

0.35

<.001

<.001

0.36

0.41

0.84

0.002

0.49

0.96

0.01

<.001

0.001

4.7

4.5

3.5

3.7

6.3

5.3

5.2

5.5

5.8

5.0

4.0

2.7

3.5

3.6

M

(4.30, 5.06)

(4.11, 4.93)

(3.05, 3.87)

(3.25, 4.20)

(5.97, 6.55)

(4.92, 5.62)

(4.81, 5.53)

(5.08, 5.91)

(5.47, 6.04)

(4.56, 5.38)

(3.49, 4.50)

(2.23, 3.17)

(3.13, 3.87)

(3.25, 4.01)

95% CI

5.0

5.4

3.8

4.2

5.9

5.3

5.4

5.4

6.2

5.2

4.0

2.8

3.6

4.3

M

(4.70, 5.27)

(5.10, 5.73)

(3.46, 4.08)

(3.81, 4.53)

(5.72, 6.15)

(5.04, 5.57)

(5.13, 5.66)

(5.11, 5.73)

(5.96, 6.39)

(4.92, 5.53)

(3.56, 4.35)

(2.45, 3.13)

(3.31, 3.86)

(3.99, 4.56)

95% CI

5.5

6.1

3.7

4.6

5.4

5.1

5.2

5.4

6.3

5.2

3.9

3.3

4.3

4.3

M

(5.27, 5.81)

(5.76, 6.36)

(3.41, 4.00)

(4.29, 4.98)

(5.19, 5.60)

(4.85, 5.36)

(4.97, 5.47)

(5.07, 5.66)

(6.12, 6.53)

(4.92, 5.50)

(3.55, 4.30)

(3.02, 3.67)

(3.99, 4.51)

(4.05, 4.59)

95% CI

12 months
M

95% CI

24 months
M

95% CI

36 months

Notes. All measures were assumed to be normally distributed in the population, so normal-theory-based estimation and tests of significance were utilized. Test statistics are Wald χ2 tests of significance for
the Time main effect for the respective child outcome. Degrees of freedom (df) was dependent on the number of observation time points: For growth parameters and ITSP scales, df=4; for the Bayley scales,
df=3; for the REEL-3 and IBQ-R, df=2. Covariance structure for Time was compound symmetric, except for growth parameters and ITSP scale, for which it was Huynh-Feldt. [A compound symmetric
structure was chosen when the Hyunh-Feldt solutions converged on a solution but produced a non-positive-definite matrix of second derivatives.] M = marginal mean estimated from the statistical model;
95% CI = 95% confidence interval. For the BSID-III, composite scores have a mean of 100 and a standard deviation of 15 in the normative sample. REEL-III composite scores likewise have a mean of 100
and a standard deviation of 15 in the normative sample. Percentile scores for both the BSID-III and the REEL-III indicate the percentage of scores equal to or below the respective mean value in the
normative sample. For the ITSP for children 3 and 6 months of age, Low Registration scores range between a low of 5 and a high of 65; Sensation Seeking: 5–30; Sensory Sensitivity: 12–60; Sensation
Avoiding: 5–25; and Low Threshold: 17–85; while for the ITSP for children 7–36 months, Low Registration: 11–55; Sensation Seeking: 14–70; Sensory Sensitivity: 11–55; Sensation Avoiding: 12–60; and
Low Threshold: 23–115. Therefore, lower ITSP scores indicate relatively more functional problems in a given area of sensory processing. Because the ITSP form administered at 3 and 6 months was
composed of 36 items, and the ITSP form administered at 12, 24, and 36 months was composed of 48 items, the 4 quadrant scores (Low Registration, Sensation Seeking; Sensory Sensitivity, and Sensation
Avoiding) and the Low Threshold score for the 36-item version were prorated by the ratio of the number of items differing between the two versions prior to analysis, to avoid an artifact in the tests of
significance due to test length. As a result, the 3- and 6-month means presented in this Table do not allow for comparison with other research. For IBR-Q scores, scores for the 14 scales (Activity Level,
Distress to Limitations, Fear, Duration of Orienting, Smiling and Laughter, High Intensity Pleasure, Low Intensity Pleasure, Soothability, Falling Reactivity/Rate of Recovery from Distress, Cuddliness,
Perceptual Sensitivity, Sadness, Approach, and Vocal Reactivity) range from a low of 1 to a high of 7, with higher scores indicating the infant has shown more of the dimension of temperament that was
rated by the mother.

19.2

2.0

Falling Reactivity/Rate of Recovery from
Distress

Vocal Reactivity

1.8

Soothability

2.1

0.3

Low Intensity Pleasure

48.0

12.1

High Intensity Pleasure

Approach

1.4

Sadness

0.1

9.0

Fear

Smiling and Laughter

20.3

Distress to Limitations

Duration of Orienting

13.0

Activity Level

Infant Behavior Questionnaire Revised (IBQ-R):

P

Author Manuscript
χ2

6 months

Author Manuscript

3 months

Author Manuscript

Time:
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5.3
7.8
2.3

Legal Composite Score

Family/Social Composite Score

24.6

Child Domain

Alcohol Composite Score

2.3

Spouse/Parenting Partner Relationship

6.5

5.2

Depression

4.2

3.0

Role Restriction

Drug Composite Score

5.7

Health

Employment Composite Score

8.9

Attachment

6.5

12.9

Isolation

Medical Composite Score

14.1

Competence

10.0

11.3

Acceptability

Life Stress

38.2

Mood

5.1

5.0

Demandingness

13.5

11.5

Reinforces Parent

Total Score

8.3

Adaptability

Parent Domain

8.3

χ2

Distractibility/Hype ractivity

Parenting Stress Index (PSI):

Time:

Drug Alcohol Depend. Author manuscript; available in PMC 2019 April 01.
0.68

0.10

0.26

0.17

0.38

0.16

0.04

0.01

0.27

<.01

0.68

0.27

0.56

0.22

0.06

0.01

0.01

0.02

<.001

<.001

0.02

0.08

0.08

P

0.10

0.06

0.01

0.14

0.76

0.08

17.0

210.0

117.0

90.0

16.4

18.7

18.6

12.9

11.8

11.4

27.0

10.0

7.7

16.0

9.1

22.5

24.8

M

(0.02, 0.18)

(0.02, 0.11)

(−0.00, 0.02)

(0.10, 0.19)

(0.65, 0.87)

(−0.03, 0.20)

(12.64, 21.45)

(194.25, 225.75)

(107.13, 126.85)

(81.66, 98.37)

(13.90 18.80)

(16.41, 21.01)

(16.14, 20.97)

(11.45, 14.26)

(10.30, 13.20)

(9.71, 13.15)

(24.49, 29.41)

(8.38, 11.69)

(6.57, 8.93)

(13.58, 18.34)

(7.95, 10.25)

(19.86, 25.24)

(22.77, 26.77)

95%
CI

3 months

0.12

0.10

0.00

0.16

0.76

0.24

15.0

202.5

115.0

86.9

17.3

17.5

16.9

12.0

10.4

13.3

26.6

9.7

7.9

15.3

7.9

22.7

23.9

M

(0.07, 0.17)

(0.05, 0.15)

(−0.00, 0.01)

(0.13, 0.19)

(0.68, 0.84)

(0.13, 0.35)

(11.40, 18.52)

(191.92, 213.18)

(107.86, 122.19)

(82.04, 91.70)

(15.08, 19.56)

(15.77, 19.21)

(15.16, 18.72)

(11.22, 12.73)

(9.51, 11.24)

(12.08, 14.61)

(24.79, 28.41)

(8.61, 10.70)

(7.07, 8.67)

(13.91, 16.71)

(7.14, 8.62)

(21.01, 24.39)

(22.58, 25.13)

95%
CI

6 months

0.14

0.06

0.01

0.17

0.75

0.12

12.1

220.4

122.5

95.5

18.0

19.3

18.0

12.8

11.8

14.3

28.3

11.1

8.5

17.4

8.8

24.4

24.9

M

(0.08, 0.20)

(0.02, 0.10)

(0.00, 0.02)

(0.14, 0.20)

(0.67, 0.82)

(0.05, 0.19)

(8.66, 15.47)

(208.82, 232.06)

(114.51, 130.47)

(89.00, 101.93)

(16.12, 19.80)

(17.38, 21.20)

(16.42, 19.65)

(11.66, 13.86)

(10.67, 12.84)

(13.05, 15.54)

(26.19, 30.42)

(10.04, 12.22)

(7.73, 9.31)

(15.84, 18.98)

(7.97, 9.69)

(22.27, 26.55)

(23.29, 26.42)

95%
CI

12 months

0.13

0.06

0.01

0.14

0.75

0.19

11.4

220.1

118.1

100.6

17.5

17.9

17.9

11.6

11.5

13.4

28.3

11.4

10.2

19.0

8.8

25.3

26.0

M

(0.07, 0.18)

(0.02, 0.10)

(0.00, 0.01)

(0.11, 0.17)

(0.68, 0.82)

(0.12, 0.27)

(8.59, 14.15)

(209.65, 230.53)

(111.39, 124.76)

(95.49, 105.65)

(15.91, 19.12)

(16.56, 19.31)

(16.56, 19.20)

(10.52, 12.68)

(10.67, 12.37)

(12.23, 14.61)

(26.61, 30.01)

(10.51, 12.28)

(9.35, 10.98)

(17.58, 20.40)

(8.16, 9.43)

(23.71, 26.84)

(24.76, 27.31)

95%
CI

24 months

0.09

0.03

0.01

0.12

0.70

0.22

10.5

222.2

120.7

100.2

17.1

18.0

18.3

12.0

11.7

14.0

30.1

11.8

10.1

18.8

9.3

25.1

25.1

M

(0.03, 0.15)

(−0.01, 0.07)

(0.01, 0.02)

(0.08, 0.15)

(0.62, 0.77)

(0.12, 0.31)

(7.99, 12.96)

(211.74, 232.65)

(114.30, 127.19)

(94.60, 105.84)

(15.80, 18.38)

(16.48, 19.42)

(16.91, 19.74)

(10.92, 13.06)

(10.84, 12.58)

(12.88, 15.05)

(28.53, 31.65)

(10.70, 12.83)

(9.44, 10.83)

(17.22, 20.37)

(8.55, 10.07)

(23.42, 26.78)

(23.68, 26.43)

95%
CI

36 months

Maternal Parenting Stress, Home Environment, and Addiction Severity Measures: Wald χ2 Tests of Significance, P Values, Estimated Marginal Means
(95% Confidence Intervals) for the Time Main Effect (N=96)
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Parenting Stress Index (PSI):
1.6

0.80

0.20

M

(0.10, 0.30)

95%
CI

0.18

M

(0.11, 0.26)

95%
CI

6 months

0.17

M

(0.10, 0.24)

95%
CI

12 months

0.14

M

(0.08, 0.21)

95%
CI

24 months

0.16

M

(0.10, 0.22)

95%
CI

36 months

Notes. All measures were assumed to be normally distributed in the population, so normal-theory-based estimation and tests of significance were utilized. Test statistics are Wald χ2 tests of significance for
the Time main effect for the respective maternal outcome. Degrees of freedom (df) was dependent on the number of observation time points: For the PSI and ASI, df=4; for HOME, df=2. Covariance
structure for Time was Huynh-Feldt, except for the HOME variables for which it was compound symmetric. [A compound symmetric structure was chosen when the Hyunh-Feldt solutions converged on a
solution but produced a non-positive-definite matrix of second derivatives.] M = estimated marginal mean; 95% CI = 95% confidence interval. For the PSI scale, scores on the Child domain scales
(Distractibility/Hyperactivity, Adaptability, Reinforces Parent, Demandingness, Mood, and Acceptability), Parent domain scale (Competence, Isolation, Attachment, Health, Role Restriction, Depression,
and Spouse/Parenting Partner Relationship) and Life Stress domain scales are the sum of the scores for the items within each domain (for each Child and Parent item: 1 “Strongly Agree” – 5 “Strongly
Disagree”, while for the 19 Life Stress items: 0 “No” 1 “Yes”), while the Child domain score is the sum of the scores on the 6 Child domain scales, and the Parent domain score is the sum of the scores on
the 7 Parent domain scales, and the Total Score is the sum of the Child and Parent domain scores. For the HOME scale, Responsivity scores can range between a low of 0 and a high of 11; Acceptance: 0–8;
Organization: 0–6; Learning Materials: 0–9; Involvement: 0–6; Variety: 0–5, and Total Score: 0–45. For the ASI scale, domain composite scores can range between 0 and 1, with higher scores indicating
greater severity of the problem.

Psychiatric Composite Score

P

Author Manuscript
3 months

Author Manuscript

χ2

Author Manuscript
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